98%
921
2 minutes
20
Objectives: The aim of this study was to identify the predictors of death and of reintervention after mitral valve replacement (MVR) in children.
Methods: A single-centre retrospective study was performed including 115 patients under the age of 18 undergoing MVR between 1982 and 2019. For all patients, the ratio of prosthetic valve size (diameter in mm) to weight (kg) at surgery was calculated and long-term result was assessed. The primary outcome was freedom from mitral valve (MV) re-replacement. The composite secondary outcome was freedom from death or transplant.
Results: Fifty-four patients had a previous surgical attempt to MV repair. The median age at surgery was 5.5 years (interquartile range 1.21-9.87). Death/transplant-free survival was 77 ± 4% at 5 years and 72 ± 5% at 10 years. Univariate analysis showed a size/weight ratio higher than 2 and age <2 years as significant risk factors for death or transplant. Freedom from MV re-replacement at 5 and 10 years was 90 ± 3% and 72 ± 6%, respectively. Biological prosthesis implanted at first replacement (P = 0.007) and size/weight ratio higher than 2 (P = 0.048) were predictors of reoperation. Significant upsizing (P < 0.0001) of mitral prosthesis was observed at re-replacement.
Conclusions: MVR is a viable strategy in children with unrepairable MV disease. Mortality can be predicted based on size/weight ratio and age <2 years. MV re-replacement can be performed with low morbidity and mortality and a larger-size prosthesis can often be placed at the time of redo.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1093/ejcts/ezab078 | DOI Listing |
Ann Thorac Surg
September 2025
Department of Cardiovascular Surgery, Icahn School of Medicine at Mount Sinai, New York, NY. Electronic address:
Heart Rhythm
September 2025
Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart Lung and Blood Vessel Diseases, Beijing, China. Electronic address:
Background: The effectiveness of ethanol infusion of the vein of Marshall (EIVOM) for persistent atrial fibrillation (AF) in patients with mitral valve replacement (MVR) remains to be determined.
Objectives: This study investigated the effectiveness and safety of EIVOM in catheter ablation of persistent AF in patients with MVR.
Methods: This is a retrospective case-control study.
Rev Esp Cardiol (Engl Ed)
September 2025
Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III, Madrid, España; Servicio de Cardiología, Hospital Clínico de Santiago de Compostela, Santiago de Compostela, España.
Introduction And Objectives: This report presents the 2024 activity data from the Interventional Cardiology Association of the Spanish Society of Cardiology (ACI-SEC).
Methods: All interventional cardiology laboratories in Spain were invited to complete an online survey. Data analysis was conducted by an external company and then reviewed and presented by the ACI-SEC board.
Ann Thorac Surg
September 2025
Department of Cardiac Surgery, University of Michigan, 1500 E. Medical Center Drive, Ann Arbor, MI 48109. Electronic address:
Innovations (Phila)
September 2025
Section of Cardiac Surgery, Department of Surgery, University of Chicago, IL, USA.
Objective: Port sites are a common source of perioperative bleeding in robotic cardiac surgery, which can be exacerbated by patient anatomy and anticoagulation. We present results from the liberal usage of a balloon-tipped coudé catheter for tamponade of robotic port sites during robotic mitral surgery.
Methods: All patients who underwent robotic mitral valve surgery at our institution from August 2016 to July 2022 were studied ( = 320).